Dicerna

Protein Forest, located in Watertown, MA, has developed a groundbreaking technology that allows for the rapid fractionation of proteins based on their isoelectric points. Their digital ProteomeChip dPC platform enhances the sensitivity and performance of protein analysis techniques, providing a reliable separation of complex protein mixtures into easier-to-analyze fractions, addressing the limitations of current technology. With the inherent benefits of microchip technology, such as small sample size and high throughput, Protein Forest's dPC product platform is compatible with standard analytical techniques like mass spectrometry, chromatography, and immunoblotting, making protein analysis faster and easier.Generated from the website

Senesco Technologies is engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Its platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. The company is developing its technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. It is also researching applications of its technologies that may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma and cardiovascular disease. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

John Ware Research Group (JWRG), founded in 2009 by Dr. John E. Ware Jr., is dedicated to advancing innovative patient-reported outcome (PRO) tools aimed at enhancing the measurement of health-related quality of life (QOL) outcomes in various settings, including population health surveys and clinical practice. The company is known for developing the QGEN and QDIS surveys, which provide valid and comprehensive assessments across chronic conditions and acute respiratory symptoms. With the introduction of the QGEN-8, a concise generic measure of health-related QOL, JWRG offers powerful survey logic that adapts to multiple comorbid conditions while ensuring efficient and relevant measurement. The organization prioritizes the standardization of QOL content scoring and norms, reinforcing its commitment to improving outcomes for patients and healthcare providers alike. Generated from the website